MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Government: International
Europe
*Europe: Regions
*Western Europe
Ireland
*Industry: Ireland
Amarin Corporation plc (NASDAQ: AMRN)*
Organization & Developments: Amarin
Organization & Developments: Amarin (Archives - 2018 - 2019)
Parents
Archives & Legacy
Organization & Developments: Amarin
Children
2018: Amarin Corp.: A Valuation_seekingalpha.com
2018: Amarin: 85% Of Doctors Polled At AHA Conference Intend To Prescribe Vascepa - Amarin Corporation PLC (NASDAQ:AMRN)
2018: Amarin: Buy This ~$3 Small Cap?
2018: Amarin: More Room To Run After REDUCE-IT Success_seekingalpha.com
2018: Amarin: The REDUCE-IT Study Data Will Be A Major Catalyst_seekingalpha.com
2018: Amarin's REDUCE-IT Trial: Something Fishy?
2018: The Facts About Amarin's Historic Cardiovascular Healthcare Breakthrough_seekingalpha.com
2018: Total Pharma Tracker's Daily BioPharma Focus: Amarin's Storm In A Teacup_seekingalpha.com
2018: UPDATED: Amarin scores a big win for its cardio outcomes study on Vascepa
2019: Amarin Is A Long-Term Buy With Potential Blockbuster Drug Vascepa_seekingalpha.com
2019: 6 Reasons Investors Are Nervous About Amarin's Big Date With the FDA
2019: Amarin Corp.: Rating Sell With $5 Price Target-2 Year Timeframe (70% Downside)_seekingalpha.com
2019: Amarin Corporation's Stock Heats Up on Buyout Chatter
2019: Amarin Has The Last Laugh_seekingalpha.com
2019: Amarin now says FDA plans outside panel review of its Vascepa
2019: Amarin shares soar after FDA agrees to fast-track review of its prescription strength fish oil pill for heart patients_www.cnbc.com
2019: Amarin takes application to expand Vascepa label to the FDA as M&A chatter heats up – Endpoints News
2019: Amarin: A Favorable Trade Heading Into AdComm And SNDA_seekingalpha.com
2019: Amarin: A Look At The Briefing Docs_seekingalpha.com
2019: Amarin: A Spate Of Negative News That Ultimately Does Not Matter_seekingalpha.com
2019: Amarin: A Surprise AdCom For Vascepa_seekingalpha.com
2019: Amarin: An Unfolding Growth Saga_seekingalpha.com
2019: Amarin: Biotech's 'Good News Bears' Is Bad News For Bears_seekingalpha.com
2019: Amarin: Crushes Q3 Earnings And Is Prepared For Vascepa's AdCom_seekingalpha.com
2019: Amarin: Elucidating Bullish And Bearish Claims_seekingalpha.com
2019: Amarin: FDA Throws Last Minute AdCom For Vascepa_seekingalpha.com
2019: Amarin: Hitting A New Inflection Point_seekingalpha.com
2019: Amarin: Update To Standards Of Medical Care In Diabetes Gives Vascepa A Boost seekingalpha.com
2019: Amarin: Vascepa Is Fully Fueled After Recent Offering_seekingalpha.com
2019: Amarin: Vascepa Marches Towards An Expanded Label_seekingalpha.com
2019: Amarin: Vascepa Revenues Could Be Significantly Higher Than $350 Million In 2019seekingalpha.com
2019: Amarin: Vascepa's Strong Growth Reflects The Positive Reactions From Doctors To REDUCE-IT_seekingalpha.com
2019: Amarin's Stock Could Reach $50 Per Share Soon
2019: Amarin's Underappreciated Breakthrough - Addressing Criticism And A Deep Dive Into Mineral Oil_seekingalpha.com
2019: Amarin’s Updated Guidance May Still Prove Conservative_seekingalpha.com
2019: Bullish Amarin doubling sales force in fast run-up to the big FDA decision on Vascepa – Endpoints News
2019: Does Amarin Have a Dark Horse Suitor?
2019: FDA Vascepa review spotlights new safety signals, possible mineral oil spoiler as Amarin hunts a blockbuster approval – Endpoints News
2019: Here's Why Amarin Stock Tumbled Today
2019: Rebuttal To A Bearish Article About Amarin_seekingalpha.com
2019: This Biotech Stock Just Got A Highly Anticipated FDA Approval_www.investors.com
2019: Why Amarin Is Stuck In A Trading Range_seekingalpha.com